MVP 2.35% 43.5¢ medical developments international limited

Another Positive Study, page-156

  1. 4,089 Posts.
    lightbulb Created with Sketch. 1420
    MethOxyfluraNe in InTerventiOnal Radiology (MONITOR): A randomised controlled trial
    Ross Copping et al. J Med Imaging Radiat Oncol.2024.
    https://pubmed.ncbi.nlm.nih.gov/38923825/

    Results: One hundred and sixty-nine patients received methoxyflurane and 145 received placebo. Baseline characteristics were similar between the two groups. The methoxyflurane group had lower pain and anxiety scores throughout the procedure (P < 0.001) with 2.5 times less pain (VAS 1.08/10) and 1.6 times less anxiety (VAS 0.97/10) on average. Lower post-procedure pain (mean 0.72 vs 1.44; P < 0.001) and anxiety (mean 0.55 vs 1.13; P = 0.008) were also observed with methoxyflurane. There were no drug or major procedure-related adverse events.

    Conclusion: The results of this study suggest that methoxyflurane provides safe and effective analgesia and anxiolysis for some procedures in IR.
 
watchlist Created with Sketch. Add MVP (ASX) to my watchlist
(20min delay)
Last
43.5¢
Change
0.010(2.35%)
Mkt cap ! $49.00M
Open High Low Value Volume
42.5¢ 43.5¢ 41.5¢ $47.40K 111.4K

Buyers (Bids)

No. Vol. Price($)
1 18806 42.0¢
 

Sellers (Offers)

Price($) Vol. No.
43.5¢ 3076 2
View Market Depth
Last trade - 16.10pm 11/09/2024 (20 minute delay) ?
MVP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.